Seres Therapeutics (MCRB) Total Current Liabilities (2014 - 2026)

Seres Therapeutics has disclosed Total Current Liabilities across 13 years of filings, most recently posting $20.0 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 35.26% year-over-year to $20.0 million; the TTM figure through Jun 2026 stood at $20.0 million (down 35.26% YoY), while the FY2025 annual figure was $19.3 million, down 53.13% from the prior year.
• Total Current Liabilities came in at $20.0 million for Q2 2026 at Seres Therapeutics, up from $19.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $108.3 million in Q2 2024 to a low of $19.3 million in Q4 2025.
• Average Total Current Liabilities over 5 years is $61.9 million, with a median of $71.4 million recorded in 2023.
• Year-over-year, Total Current Liabilities surged 72.07% in 2022 and sank 71.43% in 2025.
• Over 5 years, Total Current Liabilities stood at $85.6 million in 2022, then increased by 15.26% to $98.7 million in 2023, then sank by 58.22% to $41.2 million in 2024, then plunged by 53.13% to $19.3 million in 2025, then advanced by 3.67% to $20.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $20.0 million in Q2 2026, $19.3 million in Q1 2026, and $19.3 million in Q4 2025.